Excessive opioid prescriptions after total joint arthroplasty (TJA) increase risks for adverse opioid related events, chronic opioid use, and increase the availability of opioids for unlawful diversion. Thus, decreasing postoperative prescriptions may improve quality after
Introduction and Objective. An important subset of patients is dissatisfied after total joint arthroplasty (TJA) due to residual functional impairment. This study investigated the assessment of objectively measured step-up performance following
The most common reasons for total joint arthroplasty (TJA) failure are aseptic loosening (AL) and prosthetic joint infection (PJI). There is a big clinical challenge to identify the patients with high risk of AL/PJI before the
Background. Inflammation and chemokines play a pivotal role in aseptic loosening (AL) and prosthetic joint infection (PJI) of total joint arthroplasty (TJA). Recently, the Duffy antigen receptor for chemokines (DARC) on erythrocytes was identified as a potent chemokine receptor able to bind and carry without deactivating a wide range of CXC and CC chemokines from circulation to tissues. The role of DARC and its functional polymorphism (SNP) influencing the number of the DARC molecules on the erythrocytes in AL/PJI has not been studied yet. Methods. We genotyped functional polymorphism in the DARC gene (rs12075) using MassArray technology (Agena Bioscience) in 354 patients with
Background. Complete and reliable outcome assessment is important for clinical quality control and research evidence. Online questionnaires offer the opportunity to perform follow-up at distance and desired frequency saving efforts and cost to patients and hospitals increasingly not reimbursed for this service. Patients in this unique study have been invited by mail (not at visit or by phone) and were asked to complete both methods (online, paper) instead of only one option. For the first time, response, completion and reliability of the HOOS, KOOS-PS and New-KSS, popular patient-reported outcomes (PROM's) in
Background. Smoking has been associated with poor tissue oxygenation and vascularisation, predisposing smokers to a higher risk for postsurgical infections. The aim of this study was to estimate and compare the incidence of prosthetic joint infection (PJI) following primary total joint arthroplasty (TJA) according to smoking status. Methods. A prospective hospital-registry based cohort was used including all primary total knee and hip arthroplasties performed between 03/1996 and 12/2013 and following them until 06/2014. Smoking status at time of surgery was classified in never, former and current smoker. Incidence rates and incidence rate ratios (IRR) for PJI according to smoking status were assessed within the first year and over the whole study period. Adjusted IRRs were obtained using cox regression model. Adjustment was performed for the following baseline characteristics: age, sex, BMI, ASA score, diabetes, arthroplasty site (knee or hip) and surgery duration. Results. We included 8,559 TJAs, 3,361 knee and 5,198 hip arthroplasties. Mean age was 70 years, 61% were women, mean follow-up time was 77 months. 5,722 were never (group 1), 1,315 former (group 2) and 1,522 current (group 3) smokers. Over the study period, 108 PJI occurred. Incidence rates of infection within one year were for group 1, 2 and 3, respectively: 4.7, 10.1 and 10.9 cases/1000 person-year. Comparing ever- vs. never-smokers, the adjusted IRR was 1.84 (95% CI 1.05–3.2). Incidence rates for infection over the whole study period were 1.5, 3.1 and 2.7 cases/1000 person-years for group 1, 2 and 3, respectively. Adjusted IRR for ever- vs. never-smokers was 1.46 (95% CI 0.97–2.19). Conclusions. Smoking was associated with an about 1.5 times higher incidence rate of PJI following
The objective of this study is to determine an optimal antibiotic-loaded
bone cement (ALBC) for infection prophylaxis in total joint arthroplasty
(TJA). We evaluated the antibacterial effects of polymethylmethacrylate
(PMMA) bone cements loaded with vancomycin, teicoplanin, ceftazidime,
imipenem, piperacillin, gentamicin, and tobramycin against methicillin-sensitive Objectives
Methods